Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study

NCT03336983 is registered in ClinicalTrials.gov with Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia as lead sponsor.

NCT NCT03336983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03336983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study
Lead sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2017
Completion date
April 1, 2023
Enrollment
126 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, prostate cancer